Sanofi Cash on Hand 2012-2026 | SNY
Sanofi cash on hand from 2012 to 2026. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
- Sanofi cash on hand for the quarter ending June 30, 2026 was $7.383B, a 57.65% decline year-over-year.
- Sanofi cash on hand for 2025 was $8.663B, a 7.59% increase from 2024.
- Sanofi cash on hand for 2024 was $8.052B, a 14.59% decline from 2023.
- Sanofi cash on hand for 2023 was $9.427B, a 29.75% decline from 2022.
|
Sanofi Annual Cash on Hand (Millions of US $) |
|
|---|---|
| 2025 | $8,663 |
| 2024 | $8,052 |
| 2023 | $9,427 |
| 2022 | $13,419 |
| 2021 | $11,947 |
| 2020 | $15,895 |
| 2019 | $10,558 |
| 2018 | $8,178 |
| 2017 | $11,659 |
| 2016 | $11,368 |
| 2015 | $10,281 |
| 2014 | $10,048 |
| 2013 | $11,214 |
| 2012 | $8,436 |
| 2011 | $5,985 |
|
Sanofi Quarterly Cash on Hand (Millions of US $) |
|
|---|---|
| 2026-06-30 | $7,383 |
| 2026-03-31 | $6,489 |
| 2025-12-31 | $8,663 |
| 2025-09-30 | $10,410 |
| 2025-06-30 | $17,436 |
| 2025-03-31 | $8,419 |
| 2024-12-31 | $8,052 |
| 2024-06-30 | $7,318 |
| 2023-12-31 | $9,427 |
| 2023-06-30 | $8,716 |
| 2022-12-31 | $13,419 |
| 2022-06-30 | $7,342 |
| 2021-06-30 | $11,714 |
| 2017-12-31 | $11,659 |
| 2017-06-30 | $11,967 |
| 2016-12-31 | $11,368 |
| 2016-06-30 | $7,010 |
| 2015-06-30 | $5,450 |
| 2014-06-30 | $6,000 |
| 2013-06-30 | $5,567 |
| 2012-06-30 | $5,960 |
| 2011-12-31 | $5,985 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $105.050B | $49.347B |
| Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $1071.528B | 36.15 |
| Johnson & Johnson (JNJ) | United States | $641.804B | 24.52 |
| AbbVie (ABBV) | United States | $462.493B | 24.08 |
| Merck (MRK) | United States | $357.370B | 45.12 |
| Roche Holding AG (RHHBY) | Switzerland | $349.105B | 0.00 |
| Novartis AG (NVS) | Switzerland | $265.214B | 16.01 |
| Novo Nordisk (NVO) | Denmark | $194.004B | 10.81 |
| Pfizer (PFE) | United States | $157.995B | 9.09 |
| Bayer (BAYRY) | Germany | $56.081B | 9.98 |
| Innoviva (INVA) | United States | $1.510B | 5.16 |